The effect of metformin treatment on VEGF and PAI-1 Levels in obese type 2 diabetic patients

ERSOY C., Kiyici S., BUDAK F., ORAL H. B., Guclu M., Duran C., ...Daha Fazla

DIABETES RESEARCH AND CLINICAL PRACTICE, cilt.81, sa.1, ss.56-60, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 81 Sayı: 1
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1016/j.diabres.2008.02.006
  • Dergi Adı: DIABETES RESEARCH AND CLINICAL PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.56-60
  • Anahtar Kelimeler: type 2 diabetes mellitus, obesity, metformin, VEGF, PAI-1, ENDOTHELIAL GROWTH-FACTOR, C-REACTIVE PROTEIN, PLASMINOGEN-ACTIVATOR INHIBITOR-1, CARDIOVASCULAR RISK-FACTORS, GLUCAGON-LIKE PEPTIDE-1, INSULIN RESISTANCE, CIRCULATING LEVELS, TERM TREATMENT, MELLITUS, MARKERS
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

The aim of the study was to evaluate the effect of metformin on markers of endothelial function, vascular inflammation and factors of thrombosis in obese type 2 diabetic patients. Twenty-four type 2 diabetic patients (15 female, 9 male) previously under medical nutrition treatment (MNT) + regular exercise programme (REP) without chronic micro or macrovascular complications with the mean age of 50.5 +/- 1.5 years, diabetes duration of 17.9 +/- 6.3 months and body mass index (BMI) of 31.7 +/- 0.8 kg/m(2) were enrolled in the study. In the first 4 weeks, all the patients continued MNT + REP. In the following 12 weeks, metformin (mean daily dosage of 1381 +/- 85 mg) was added. After the first period with MNT + REP, BMI, waist circumference, fat percentage, blood pressure and HDL cholesterol decreased significantly. After metformin addition, there was a significant decrement in BMI, waist circumference, fat percentage, fasting and postprandial. plasma glucose, hemoglobin A1C, plasminogen activator inhibitor-1 (PAI-1), vascular endothelial growth factor (VEGF) and increment in P cell reserve values of the patients. Our results indicated that, metformin addition had beneficial effect on VEGF and PAI-1 levels in obese type 2 diabetic patients under MNT + REP, independent from its' favourable effects on BMI and glycemic control. (C) 2008 Elsevier Ireland Ltd. All rights reserved.